Search results
Results From The WOW.Com Content Network
The company had 257.4 million shares of common stock outstanding as of June 30th, 2024. Total operating expenses for the three months ended June 30th, 2024 were $16.6 million included research and ...
Covaxin (development name, BBV152) is a whole inactivated virus -based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology. [2]
The reason for investing in Ocugen (NASDAQ:OCGN) stock hasn’t changed. Bulls expect the FDA to allow Ocugen to market Bharat Biotech’s Covaxin vaccine in the U.S., enabling Ocugen to generate ...
On Oct. 27, Ocugen (NASDAQ:OCGN) confirmed the truth of a point I’ve been making for many months: the FDA will require the company to conduct a U.S.-based trial of Covaxin before the agency will ...
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States. The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, [7] and mass vaccinations began four days later.
Institutions. University of Pennsylvania. Castleman Disease Collaborative Network. David C. Fajgenbaum (born March 29, 1985) is an American immunologist and author who is currently an assistant professor at the Perelman School of Medicine of the University of Pennsylvania. [1] He is most well known for his research into Castleman disease.
Ocugen Inc (NASDAQ: OCGN) rises sharply after announcing the sale of 3 million common shares at $7.65 per share in a registered direct offering, with gross proceeds of $23 million. The offer price ...
Oxygen toxicity is a condition resulting from the harmful effects of breathing molecular oxygen (O. 2) at increased partial pressures. Severe cases can result in cell damage and death, with effects most often seen in the central nervous system, lungs, and eyes. Historically, the central nervous system condition was called the Paul Bert effect ...